Ignite Creation Date:
2024-07-17 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06488378
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-28
Brief Title:
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA12 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
| PALB2-Mutated Breast Carcinoma |
| HER2-negative Breast Cancer |
| BRCA1 Mutation |
| BRCA2 Mutation |